COMMUNIQUÉS West-GlobeNewswire

Nxera Pharma to Host R&D Day 2024
18/10/2024
Nxera Pharma Co., Ltd. will hold an R&D Day on 6 November 2024 at 16:30 JST. The meeting will be held virtually via Zoom webinar. Please click here to pre-register for the event. Date : Wednesday, 6 November 2024 [...]
Novo Nordisk A/S: Alhemo® recommended for European approval as first once-daily subcutaneous prophylactic treatment for people living with haemophilia A or B with inhibitors
18/10/2024
Bagsværd, Denmark, 18 October 2024 – Novo Nordisk today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending approval of [...]
ITM and NTP Strengthen Global Radioisotope Production Capacities by Renewing their Technology License Agreement and Signing a Manufacturing and Supply Agreement for n.c.a. Lutetium-177
18/10/2024
Extension of 2012 agreement grants NTP the rights to manufacture and distribute non-carrier-added Lutetium-177 (n.c.a. 177 Lu) Companies enter into an additional manufacturing and supply agreement for NTP to produce and [...]
Fortrea publie son premier rapport de Responsabilité Sociale d’Entreprise
18/10/2024
DURHAM, Caroline du Nord, 18 oct. 2024 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq : FTRE), l’un des principaux organismes internationaux de recherche sous contrat (CRO), a annoncé aujourd’hui la publication du premier rapport [...]
Telix Files Form 20-F Registration Statement for Nasdaq ADS
17/10/2024
MELBOURNE, Australia, Oct. 18, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) announces that it has publicly filed a Form 20-F registration statement (Registration Statement) with [...]
Laguna Treatment Center Sets Standard for Veteran Addiction Care in Southern California with New PsychArmor Certification
17/10/2024
ALISO VIEJO, Calif., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Laguna Treatment Center is among an elite group of addiction treatment providers who have earned Veteran Ready status from PsychArmor, a leader in military culture [...]
Tenaya Therapeutics Announces Updates on TN-201 Gene Therapy Program for MYBPC3-associated HCM
17/10/2024
Independent Data Safety and Monitoring Board Endorsed Dose Escalation and Broadening of Eligibility Criteria; Cohort 2 Now Enrolling Initial Data from Cohort 1 to be Reported in December 2024 Highlights Recently [...]
Profound Medical to Release Third Quarter 2024 Financial Results on November 7 – Conference Call to Follow
17/10/2024
TORONTO, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free [...]
LifeStance to Host Third Quarter 2024 Earnings Conference Call on November 7, 2024
17/10/2024
SCOTTSDALE, Ariz., Oct. 17, 2024 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (NASDAQ: LFST), one of the nation’s largest providers of outpatient mental health care, will issue its third quarter 2024 earnings [...]
Supernus Announces Promising Data from Open-Label Phase 2a Study of SPN-820 in Adults with Major Depressive Disorder
17/10/2024
Phase 2a study demonstrated rapid and substantial decrease in depressive symptoms SPN-820 was well-tolerated with few adverse events SPN-820 is a novel, first-in-class intracellular modulator of mTORC1 for the treatment [...]
Sight Sciences to Report Third Quarter Financial Results on November 7, 2024
17/10/2024
MENLO PARK, Calif., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, [...]
Multiple Clinical Complete Responses Demonstrated Following Single Low Dose Administration of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) in Ongoing Phase 1 Trial
17/10/2024
Clinical Complete Responses Observed in 4 out of 5 Patients in Subset of Patients with Low Grade Disease; Evidence of Bladder Urothelial Field Effect in Non-Target Tumors Favorable Safety Profile Observed; Only Grade 1 [...]
TELA Bio to Announce Third Quarter 2024 Financial Results
17/10/2024
MALVERN, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today [...]
23andMe Introduces New Feature Helping African Americans Trace Their Roots to Post Slavery Communities in the South
17/10/2024
The new African American Genetic Groups feature traces customers' ancestral connections from before the early-to-mid-20th century migrations to more than 200 communities in Southern states SUNNYVALE, Calif., Oct. 17, [...]
ClearPoint Neuro to Announce Third Quarter 2024 Results November 7, 2024
17/10/2024
SOLANA BEACH, Calif., Oct. 17, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine [...]
Seer to Report Third Quarter 2024 Financial Results on November 6, 2024
17/10/2024
REDWOOD CITY, Calif., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial [...]
Intuitive Announces Third Quarter Earnings
17/10/2024
SUNNYVALE, Calif., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Intuitive (the “Company”) (Nasdaq: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced financial [...]
Anika Announces Third Quarter 2024 Results Conference Call Date
17/10/2024
BEDFORD, Mass., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its third quarter 2024 [...]
Signature d’un avenant n°3 au contrat de financement obligataire en vigueur pour assurer le retournement stratégique de Safe
17/10/2024
Avertissement : La société SAFE SA (la « Société ») a mis en place un financement sous forme d’obligations convertibles en actions nouvelles ou existantes (OCEANE) avec Global Corporate Finance Opportunities 20 (« GCFO [...]

Pages